Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | DRD2 | P14416 | 13/20 | 0.50 |
| ▸ | DRD3 | P35462 | 3/20 | 0.50 |
| ▸ | DRD4 | P21917 | 2/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7531509 | 0.94 | GAA (0.59) | GAAMAPTDRD2DRD3DRD4 | |
| SCHEMBL7533555 | 0.88 | GAA (0.50) | GAAMAPTDRD2DRD3DRD4 | |
| SCHEMBL7531449 | 0.85 | GAA (0.56) | GAAMAPTDRD2DRD3DRD4 | |
| SCHEMBL7538054 | 0.84 | GAA (0.54) | GAAMAPTDRD2DRD3DRD4 | |
| SCHEMBL7531920 | 0.82 | GAA (0.52) | GAAMAPTDRD2DRD3DRD4 | |
| SCHEMBL7531514 | 0.79 | GAA (0.58) | GAAMAPTDRD2DRD3DRD4 | |
| SCHEMBL7532701 | 0.79 | HTR1A (0.72) | DRD2HTR1A | |
| SCHEMBL7533277 | 0.79 | DRD2 (0.53) | DRD2HTR1A | |
| SCHEMBL7533281 | 0.79 | DRD2 (0.51) | DRD2DRD3DRD4HTR1A | |
| SCHEMBL7532864 | 0.79 | DRD2 (0.55) | GAAMAPTDRD2DRD3DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020128272-A1 | 4,5,6, and 7-indole and indoline derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2002-09-12 | — | — | US | claimed |
| US-6391882-B1 | PSYCHOLOGICAL DISORDERS; ANTIDEPRESSANTS | H. LUNDBECK A/S (DK) | 2002-05-21 | — | — | US | claimed |
| US-20020128272-A1 | 4,5,6, and 7-indole and indoline derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2002-09-12 | — | — | US | disclosed |
| US-6391882-B1 | PSYCHOLOGICAL DISORDERS; ANTIDEPRESSANTS | H. LUNDBECK A/S (DK) | 2002-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128272-A1 | 4,5,6, and 7-indole and indoline derivatives, their preparation and use | HTR2C, HTR1A, HTR7 | GAA 4549/4885MAPT 2061/4885DRD2 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.